为儿科用剂型选择合适的辅助剂 - - 儿科辅助剂风险评估 (PERA) 框架 - - 第1部分
Smita Salunke1, Anjali Agrawal2, Jennifer Walsh3
1European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK.
概括
为儿科药物配方选择安全的辅助剂是一项挑战. 拟议的儿科辅助剂风险评估 (PERA) 框架提供了一种系统的方法来评估辅助剂的风险,并改善儿童群体的决策.
科学领域:
- 制药科学 制药科学
- 药物的配方 药物的配方
- 儿科药理学 儿科药理学
背景情况:
- 助剂是影响药物产品性能,稳定性和安全性的关键配方成分.
- 选择适当的辅助剂,具有足够的安全性和耐受性是儿科配方开发的一个重大挑战.
- 辅助剂在儿科患者群体中的适用性取决于年龄范围,使用模式 (急性与慢性) 和临床风险益处分析.
研究的目的:
- 为了解决缺乏系统方法来选择辅助剂和评估儿科配方中的风险.
- 引入一个结构化的决策框架,用于辅助剂在儿科药物开发中的使用.
- 为了提高透明度和沟通,关于辅助剂的选择和儿童使用的理由.
主要方法:
- 儿童辅助剂风险评估 (PERA) 框架的制定和提议.
- 在PERA框架内整合可定制的工具和流程.
- 关于在特定儿科环境中评估辅助剂适用性的风险-益处原则的指导.
主要成果:
- PERA框架提供了一个结构化和系统的决策过程.
- 该框架旨在改善对儿科配方中辅助剂风险的评估.
- 促进了助剂选择和证明的提高透明度和沟通.
结论:
- 系统的方法对于辅助剂在儿科配方中安全有效地使用至关重要.
- PERA框架为参与儿科药物开发的科学家和监管机构提供了有价值的工具.
- 实施PERA框架可以提高患者的安全性和优化儿科药品.
相关概念视频
Factors Influencing Drug Absorption: Pharmaceutical Parameters
123
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
123
Factors Affecting Drug Response: Overview
1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Preclinical Development: Overview
4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Analysis of Population Pharmacokinetic Data
241
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
241
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
Bioequivalence: Overview
949
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
949


